The 6 AM Blind Spot: How HBox Captures the Cardiovascular Risk Your EHRs Never See

Cardiovascular events like heart attacks spike in the early morning hours, but the precise mechanism has been unclear—until now. Groundbreaking research from our newly appointed CMO, Dr. Rahul Chaudhary, published in the Journal of Thrombosis and Thrombolysis, finally explains why. His findings independently validate what HBox has been capturing for five years: the time-resolved physiological patterns that create cardiovascular risk—patterns traditional systems never see. Dr. Chaudhary's research has been cited in four American Heart Association Scientific Statements and the 2024 ACC/AHA Perioperative Cardiovascular Management Guidelines, shaping how clinicians worldwide approach time-dependent cardiovascular risk. https://pubmed.ncbi.nlm.nih.gov/36074227/

The Study: What Aspirin Couldn't Stop

The study serially monitored 37 high-risk, aspirin-treated patients with Type II Diabetes over a 24-hour period. The finding was stark: even while on aspirin, the speed of clot initiation was significantly faster during the 5 AM to 7 AM awakening window than at other times of day. Pulse pressure also peaked during these critical hours.

The Data Gap: Why EHRs Miss the Danger Zone

Here's why this matters: Dr. Chaudhary's study required round-the-clock monitoring in a clinical research facility to uncover these patterns. This is not scalable. Traditional EHRs and clinical trials capture patient data episodically, maybe once every 3-6 months. They see that a patient is "on aspirin" but are completely blind to the daily, hourly physiological changes that create this window of intense risk. HBox makes collecting this time-resolved data practical and scalable for the first time.

HBox Captures What Everyone Else Misses

6 AM blood pressure spikes, not "morning averages"

Instead of "morning" averages, see a patient's pulse pressure spike at 6:15 AM, 30 minutes after waking. Correlate it to symptoms and medication timing, not just a quarterly clinic visit.

See when patients actually take their meds:

Discover that your patient takes their hypertension medication at 10 PM instead of 8 AM, immediately explaining their uncontrolled morning blood pressure surge. Clinical trials assume perfect adherence. HBox shows reality.

Catch warning signs weeks before events:

Track how a COPD patient's peak flow drops 15% every morning around 6:30 AM for two weeks, revealing a critical pattern that precedes a costly exacerbation—a pattern invisible in standard PFT tests.

While Dr. Chaudhary's research focused on cardiovascular risk, the same time-resolved approach reveals hidden patterns in pulmonology, metabolic conditions, and any therapeutic area where timing matters—which is all of them.

The HBox Difference: A Higher Resolution of Reality

Platform Type	What It Captures	What It Misses
EHRs	Quarterly clinic visits	The 99% of time between visits
Wearables	Step counts, heart rate averages	Medication timing, symptoms, context
Standard RPM	Daily average vitals	Hour-by-hour patterns, behavioral triggers
HBox	Time-stamped meds + symptoms + vitals in one timeline	Nothing. That's the point.

See the Data Your Clinical Trials Are Missing

Traditional RWE captures what happens during a 15-minute doctor visit. HBox captures what happens in the 99% of time between visits—when risk actually peaks, when medications fail, when interventions work or don't. Dr. Chaudhary's research proved that in cardiovascular risk, timing is everything. HBox is the only platform built to capture it.

HBox has been collecting time-resolved patient data for five years across:  Dr. Chaudhary joined as CMO because his research independently proved what we've been demonstrating in real-world clinical practice: traditional data collection misses the patterns that matter most. His research validates our approach. Our platform proves it scales.

Ready to see the data difference?

Source: Chaudhary R, Sharma T, Tantry US, Asgar JA, Kundan P, Duhan S, Gill H, Singh A, Alasadi Y, Gurbel PA, Bliden KP. Serial assessment of thrombogenicity and hemodynamics in patients with type II diabetes in a clinical research unit: Evidence for circadian variations in clot formation. J Thromb Thrombolysis. 2022 Oct;54(3):393-400. doi: 10.1007/s11239-022-02699-1. Epub 2022 Sep 8. PMID: 36074227.